Learnings from FDA‐Approved Bispecific Antibodies in Oncology ...

Bispecific antibodies, by enabling the targeting of more than one disease-associated antigen or engaging immune effector cells, ...

Learnings from FDA- Approved Bispecific Antibodies in Oncology

Clinical pharmacology strategies, including dose- related strategies, are critical for bispecific antibody development. This analysis reviewed clinical studies ...

Clinical Pharmacology Strategies for Bispecific Antibody Development

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies in Oncology · Abstract.

Bispecific Antibodies: An Area of Research and Clinical Applications

Since 2014, FDA has approved nine BsAb marketing applications to treat cancer, as well as hematologic and ocular diseases. (See chart below). In ...

Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy

Bispecific antibody-based immunotherapies have gained momentum in preclinical and clinical investigations following the regulatory approval of the T cell– ...

Learnings from FDA-Approved Bispecific Antibodies in Oncology

Download Citation | Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA-Approved Bispecific Antibodies ...

Learnings from FDA-Approved Bispecific Antibodies in Oncology ...

Bispecific antibodies, by enabling the targeting of more than one disease-associated antigen or engaging immune effector cells, have both advantages and ...

Bispecific Antibody Immunotherapy - Cancer Support Community

They also are not used for all types of cancer at this time. The FDA has approved the use of bispecific antibody drugs in certain patients with ALL. Some ...

Bispecific antibodies: advancing precision oncology: Trends in Cancer

Thus far, a total of seven bsAbs have received regulatory approval for use in hematological malignancies and four in select solid tumors, with ...

'Switchable' bispecific antibodies pave way for safer cancer treatment

Immunotherapy utilizing an FDA-approved drug has enabled Penn researchers to develop a novel switchable bispecific T cell engager that mitigates ...

Bispecific Antibody Therapies for Lymphoma - Dana-Farber

Three bispecific antibody therapies have been FDA approved with more on the horizon. ... cancer care centers develop an approach to ...

Utilization Challenges Hold Back the Adoption of Bispecific Therapies

According to the FDA, what makes bispecific antibodies a landscape-changing therapy that will potentially lead to a large number of new ...

Bispecific Antibodies: A New Frontier in Immunotherapy

The advances in immunotherapy in cancer care are ever-changing and complex. It is integral for nurses to have current knowledge of ...

How Can Bispecific Antibodies Treat Blood Cancer?

Besides the recent approval of teclistamab to treat multiple myeloma, the FDA in December gave another bispecific antibody “Breakthrough Therapy ...

String of Recent Approvals Puts Spotlight on Bispecifics

In August, talquetamab-tgvs—a bispecific antibody directed against CD3 and GPRC5D—received FDA accelerated approval and European Commission ...

The promise of bispecific antibodies: Clinical applications and ...

Currently, blinatumomab is the only BsAb approved for cancer therapy (Fig. 1). More recently, JNJ-6372 (EGFR × MET) received FDA breakthrough therapy ...

USING BISPECIFIC ANTIBODIES IN COMMUNITY PRACTICE ...

Successful administra- tion of BsAbs requires competence and effective collaboration among multidisciplinary providers on the cancer care team. BLINATUMOMAB: ...

Treating Cancer with Bispecific Antibodies: New FDA Approvals

Treating Cancer with Bispecific Antibodies: New FDA Approvals · Table. Bispecific T-cell-Engaging Antibodies Granted FDA Accelerated Approval in ...

Demystifying Bispecific Antibodies for Hematologic Malignancies

As of November 2019, the FDA has approved one bispecific antibody for the treatment of cancer: blinatumomab. The drug binds to CD3 on T ...

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the ...